{"organizations": [], "uuid": "28d282fb2b95f8becbbd4cc31d332c6ef77cedda", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-hikma-gets-us-fda-response-on-anda/brief-hikma-gets-u-s-fda-response-on-anda-for-generic-version-of-gsks-advair-diskus-idUSFWN1QT086", "country": "US", "domain_rank": 408, "title": "BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T09:37:00.000+02:00", "replies_count": 0, "uuid": "28d282fb2b95f8becbbd4cc31d332c6ef77cedda"}, "author": "", "url": "https://www.reuters.com/article/brief-hikma-gets-us-fda-response-on-anda/brief-hikma-gets-u-s-fda-response-on-anda-for-generic-version-of-gsks-advair-diskus-idUSFWN1QT086", "ord_in_thread": 0, "title": "BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus", "locations": [], "entities": {"persons": [{"name": "gen", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "advair", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}, {"name": "advair diskus reuters", "sentiment": "none"}, {"name": "hikma pharmaceuticals plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "glaxosmithkline", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 7:39 AM / Updated 20 minutes ago BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus Reuters Staff March 12 (Reuters) - Hikma Pharmaceuticals Plc: * UPDATE STATUS ON ANDA FOR GENERIC ADVAIR DISKUS * HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE’S ADVAIR DISKUS * REMAINED OUTSTANDING ISSUE REGARDING CLINICAL ENDPOINT STUDY, IN RESPONSE, DECIDED TO ENGAGE IN FDA’S DISPUTE RESOLUTION PROCESS​ * HIKMA HAS ALREADY FINALISED PLANNING OF A NEW CLINICAL STUDY AND EXPECTS TO START PATIENT ENROLMENT IN COMING WEEKS * ‍HIKMA ANTICIPATES BEING ABLE TO SUBMIT A RESPONSE TO FDA WITH NEW CLINICAL DATA AS EARLY AS POSSIBLE IN 2019​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T09:37:00.000+02:00", "crawled": "2018-03-12T10:08:22.027+02:00", "highlightTitle": ""}